Article Sidebar
Published:
Apr 10, 2026DOI:
10.4314/tjpr.v25i3.7Keywords:
Article Details
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
Main Article Content
Comparative efficacy of N-Acetylcysteine (NAC) and rutin in ameliorating paclitaxel-induced hepatotoxicity in male rats
Abstract
Purpose: To analyze the hepatoprotective properties of N-acetylcysteine (NAC) and rutin (RU) via a rat model of paclitaxel (PAC)-induced hepatotoxicity.
Methods: Forty male Swiss albino rats were divided into four groups containing ten rats each. Paclitaxel (2 mg/kg) was administered intraperitoneally (ip) to all groups on days 1 and 7, except the control group, which received only distilled water orally. Rutin (40 mg/kg/day) was administered orally to the paclitaxel + rutin group, while 50 mg/kg/day of N-acetylcysteine was administered orally to the paclitaxel + N-acetylcysteine group. The treatments lasted for 14 days, during which liver weight, body weight change, Serum levels of Tumor necrosis factor-alpha (TNF-α) and Interleukin-10 (IL-10) were measured using enzyme-linked immunosorbent assay (ELISA), and histopathology of liver tissues was examined to evaluate tissue damage.
Results: Groups that received PAC had significantly reduced liver weight and increased serum IL-10 as well as TNF-α levels in comparison to control group (p < 0.05). The use of NAC and rutin mitigated these effects. Paclitaxel + N-acetylcysteine group showed a more significant reduction in inflammatory markers, with levels approaching values in control group (p < 0.05). Histologically, PAC caused severe hepatic damage, whereas NAC and RU preserved liver architecture, with NAC offering better protection.
Conclusion: N-acetylcysteine and rutin were equally effective in attenuating PAC-induced hepatotoxicity, with N-acetylcysteine showing superior anti-inflammatory effect and rutin better structural protection. These findings suggest that both are promising adjuvants for PAC chemotherapy.
